Reviva Pharmaceuticals Holdings Inc. (RVPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has a cash flow conversion efficiency ratio of -1.229x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.59 Million) by net assets ($4.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Reviva Pharmaceuticals Holdings Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Reviva Pharmaceuticals Holdings Inc. (RVPH) total liabilities for a breakdown of total debt and financial obligations.
Reviva Pharmaceuticals Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allwin Telecommunication Co Ltd
SHE:002231
|
-0.069x |
|
Unite Group PLC
LSE:UTG
|
0.019x |
|
Axita Cotton Limited
NSE:AXITA
|
0.009x |
|
Kodi-S Co Ltd
KQ:080530
|
0.033x |
|
Haiwan International Development Co Ltd
TWO:3252
|
0.019x |
|
111 Inc
NASDAQ:YI
|
0.174x |
|
Trajectory Alpha Acquisition Corp
NYSE:TCOA
|
-0.004x |
|
Yong Shun Chemical Co Ltd
TWO:4711
|
0.022x |
Annual Cash Flow Conversion Efficiency for Reviva Pharmaceuticals Holdings Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Reviva Pharmaceuticals Holdings Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $812.57K | $-33.54 Million | -41.281x | -733.47% |
| 2023-12-31 | $5.72 Million | $-28.32 Million | -4.953x | -119.28% |
| 2022-12-31 | $8.39 Million | $-18.96 Million | -2.259x | -507.36% |
| 2021-12-31 | $28.69 Million | $-10.67 Million | -0.372x | +50.01% |
| 2020-12-31 | $5.47 Million | $-4.07 Million | -0.744x | -2419.97% |
| 2019-12-31 | $-6.81 Million | $-218.44K | 0.032x | +277.08% |
| 2018-12-31 | $59.16 Million | $-1.07 Million | -0.018x | -- |
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, i… Read more